1

1	XBB.1.5 mRNA COVID-19 Vaccination and Inpatient or Emergency Department Visits
2	Among Adults Infected with SARS-CoV-2 JN.1 and XBB-Lineage Variants
3	
4	Matthew E. Levy <sup>1</sup> , Vanessa Chilunda <sup>1</sup> , Phillip R. Heaton <sup>2</sup> , Deran McKeen <sup>3</sup> , Jason D.
5	Goldman <sup>4,5,6</sup> , Richard E. Davis <sup>7</sup> , Cynthia A. Schandl <sup>8</sup> , William B. Glen <sup>8</sup> , Lisa M.
6	McEwen <sup>1</sup> , Elizabeth T. Cirulli <sup>1</sup> , Dana Wyman <sup>1</sup> , Andrew Dei Rossi <sup>1</sup> , Hang Dai <sup>1</sup> , Magnus
7	Isaksson <sup>1</sup> , Nicole L. Washington <sup>1</sup> , Tracy Basler <sup>1</sup> , Kevin Tsan <sup>1</sup> , Jason Nguyen <sup>1</sup> , Jimmy
8	Ramirez <sup>1</sup> , Efren Sandoval <sup>1</sup> , William Lee <sup>1</sup> , James Lu <sup>1</sup> , Shishi Luo <sup>1</sup>
9	
10	<sup>1</sup> Helix, San Mateo, California, USA; <sup>2</sup> Department of Pathology and Laboratory Medicine,
11	HealthPartners, Bloomington, Minnesota, USA; <sup>3</sup> HealthPartners Institute, Bloomington,
12	Minnesota, USA; <sup>4</sup> Providence St. Joseph Health System, Renton, Washington, USA;
13	<sup>5</sup> Swedish Center for Research and Innovation, Swedish Medical Center, Seattle,
14	Washington, USA; <sup>6</sup> Division of Infectious Disease, University of Washington, Seattle,
15	Washington, USA; <sup>7</sup> Providence Sacred Heart Medical Center and Children's Hospital,
16	Spokane, Washington, USA; <sup>8</sup> Department of Pathology and Laboratory Medicine,
17	Medical University of South Carolina, Charleston, South Carolina, USA
18	
19	Corresponding author: Matthew Levy, PhD. Helix. Mail: 101 S. Ellsworth Avenue, Suite
20	350, San Mateo, CA 94401. Email: matt.levy@helix.com.
21	

2

# 23 ABSTRACT

- 24 Within a multi-state viral genomic surveillance program, we conducted a case-control
- analysis comparing prior receipt of XBB.1.5-adapted mRNA vaccination between
- 26 SARS-CoV-2-infected adults with inpatient/ED visits (proxy for severe illness) vs
- 27 outpatient visits. Among 6,551 patients from September 2023-January 2024, 6.1% with
- inpatient/ED visits vs 12.0% with outpatient visits had received XBB.1.5 vaccination
- 29 (aOR=0.41; 95%CI:0.32-0.53). This protective association was weaker among JN.1
- 30 (aOR=0.62; 95%CI:0.40-0.96) vs XBB-lineage (aOR=0.28; 95%CI:0.18-0.43) variant
- 31 infections (interaction, p=0.003). XBB.1.5 vaccination was also protective specifically
- 32 compared to BA.4/BA.5-adapted mRNA vaccination (aOR=0.60; 95%CI:0.45-0.79).
- 33 XBB.1.5 vaccines protect against severe illness, but protection may be weaker against
- 34 JN.1 vs XBB-lineage variants.

# 3

# 35 INTRODUCTION

36	On 11 September 2023, the US Food and Drug Administration (FDA) approved the
37	2023-2024 BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) monovalent
38	mRNA COVID-19 vaccines for individuals aged ≥12 years, with emergency use
39	authorization granted for children aged 6 months to 11 years. These vaccines target the
40	spike protein of the SARS-CoV-2 Omicron variant XBB.1.5, which was predominant in
41	the US from January to May 2023 [1]. The US Centers for Disease Control's (CDC's)
42	Advisory Committee on Immunization Practices (ACIP) subsequently recommended
43	that individuals aged ≥6 months receive an XBB.1.5-adapted vaccine regardless of their
44	vaccination history, to enhance protection against circulating variants [2].
45	By September 2023, other XBB variants such as EG.5 and HV.1 (both sublineages of
46	XBB.1.9.2) had surpassed XBB.1.5 in prevalence. By late December 2023, another
47	novel variant, JN.1 (a sublineage of BA.2.86), had become predominant, accounting for
48	65% of SARS-CoV-2 infections nationwide by 6 January 2024 [1]. The rapid rise of
49	JN.1, which possesses more than 30 mutations in the spike protein compared to
50	XBB.1.5 (including the notable L455S mutation), could be attributed to increased
51	immune escape and infectivity [3,4]. In laboratory-based neutralization studies, JN.1 has
52	displayed increased resistance to neutralization by antibodies induced by XBB.1.5-
53	adapted mRNA vaccination [4-6]. However, immunogenicity studies suggest that
54	antibody titers are likely to remain effective [7]. Initial findings indicate short-term
55	effectiveness of XBB.1.5-adapted mRNA vaccines for protecting against symptomatic
56	SARS-CoV-2 infection and severe COVID-19 outcomes, largely during periods of XBB
57	predominance [8-14].

4

58	To our knowledge, no prior study has examined variant-specific estimates of XBB.1.5
59	vaccine protection against severe COVID-19 outcomes, and it remains unknown
60	whether XBB.1.5 vaccines protect against severe illness from JN.1 variant infection.
61	Here, we leverage a multi-state viral genomic surveillance program to conduct a case-
62	control analysis assessing the effect of XBB.1.5-adapted mRNA vaccination on patients'
63	likelihood of having inpatient or emergency department (ED) visits (considered severe)
64	vs outpatient visits (considered mild), among adults with medically attended SARS-CoV-
65	2 infection. Serving as an indicator of vaccine-associated protection against severe
66	illness post-infection, this association was evaluated overall and separately among JN.1
67	and XBB-lineage variant infections.

# 68 **METHODS**

# 69 **Design and Setting**

70 Within a pan-respiratory virus genomic surveillance program, residual clinical samples 71 from patients who tested positive for a respiratory virus (molecular or antigen) were 72 obtained from three health systems with facilities spanning California, Minnesota, South 73 Carolina, Washington, and Wisconsin (Supplementary Table 1). Samples were initially 74 collected from patients during medical visits and were characterized based on location 75 of collection as inpatient, ED, or outpatient. Patients' demographic characteristics and COVID-19 vaccination history were extracted from electronic health records (EHRs). 76 77 Study protocols were approved by institutional review boards.

# 78 Viral Sequencing

5

79	Viral sequencing	was performed	l by Helix	using a hyb	ridization-captu	ure based assay	r
----	------------------	---------------	------------	-------------	------------------	-----------------	---

- 80 (Twist Biosciences) and short-read genome sequencing technology (Illumina), as
- 81 previously described [15]. SARS-CoV-2 was identified in samples with reads that
- 82 aligned to the reference genome, and lineages were assigned using pangolin version
- 4.3.1. Further details are provided in the Supplementary Methods.

### 84 Study Sample

- 85 This analysis included SARS-CoV-2-positive samples collected from adults aged ≥18
- 86 years between 24 September 2023 and 21 January 2024. SARS-CoV-2 infection was
- 87 identified from either clinical diagnostic testing (performed/ordered by the health
- system), viral sequencing (performed by Helix), or both.

# 89 Visit Type

90 The clinical visit type associated with sample collection was a surrogate measure of the 91 severity of illness at time of testing. Inpatient and ED visits represented more severe 92 illness compared to outpatient visits. The reason for the visit and patients' specific 93 symptoms were not available for analysis.

# 94 Vaccination Status

95 COVID-19 vaccination status was assigned using the date and type of the most recent 96 dose received prior to the specimen collection date (regardless of the total number of 97 earlier doses received). Patients were considered to be: 1) vaccinated with an XBB.1.5-98 adapted monovalent mRNA vaccine if their last dose occurred on/after September 12, 99 2023 and was BNT162b2 or mRNA-1273; 2) vaccinated with a BA.4/BA.5-adapted

6

100	bivalent mRNA vaccine if their last dose occurred between September 1, 2022 and
101	September 11, 2023 and was BNT162b2 or mRNA-1273; 3) vaccinated with an original
102	wild-type monovalent mRNA or viral vector vaccine if their last dose occurred before
103	September 1, 2022 and was either BNT162b2, mRNA-1273, or Ad26.COV2.S; and 4)
104	unvaccinated if they had received no prior COVID-19 vaccine doses. Patients were
105	excluded if they received any dose 0-6 days before the collection date (83) or if their
106	most recent dose was a different (20) or unknown (124) vaccine type.

# 107 Statistical Analysis

108 In this case-control analysis, the odds of prior XBB.1.5 vaccination were compared 109 between inpatient or ED patients (cases) and outpatients (controls). We also compared 110 inpatient vs outpatient (excluding ED). Adjusted odds ratios (aORs) and 95% 111 confidence intervals (CIs) for the association between vaccination status and visit type 112 were calculated using multivariable logistic regression, adjusting for age group, sex, 113 race/ethnicity, health system and state of residence, and collection date (natural cubic 114 spline). In multivariable models, effect modification by variant (JN.1 vs XBB-lineage) 115 was assessed using an interaction term with vaccination status. Receipt of an XBB.1.5 116 vaccine was compared to no receipt of an XBB.1.5 vaccine (irrespective of vaccination 117 history) and to three specific reference groups: 1) BA.4/BA.5 vaccination but no XBB.1.5 118 vaccine; 2) wild-type vaccination but no BA.4/BA.5 or XBB.1.5 vaccine; and 3)

119 unvaccinated. In a separate analysis, XBB.1.5 vaccine recipients were further

120 categorized based on duration of time since their dose (7-59 vs  $\geq$ 60 days earlier). In

121 addition, BA.4/BA.5 and wild-type vaccine recipients were compared to unvaccinated.

122 Subgroup analyses were conducted among patients infected with JN.1, XBB-lineage

7

123 (any), HV.1, and EG.5 variants; among patients aged  $\geq$ 65 years; and among patients 124 with no other respiratory virus coinfection. *P*<0.05 was considered statistically significant 125 and analyses were performed using R version 4.2.3.

# 126 **RESULTS**

- 127 Among 6,551 adults with medically attended laboratory-confirmed SARS-CoV-2
- 128 infection, 1,912 (29.2%) were tested in either an inpatient (1,012; 15.4%) or ED (900;
- 129 13.7%) setting, while 4,639 (70.8%) were tested in an outpatient setting. Most SARS-
- 130 CoV-2 infections were detected through clinical diagnostic testing, with only 8 first
- 131 identified through viral sequencing. Patient characteristics stratified by visit type are
- presented in Table 1. Inpatients had a higher median age (73 years; IQR:61-82)
- 133 compared to ED patients (55 years; IQR:35-72) and outpatients (52 years; IQR:36-68).
- Lineages were successfully assigned to 4,480 samples (68.4%), with the most prevalent
- 135 variants being JN.1 (1,084; 24.2%), HV.1 (803; 17.9%), and EG.5 (746; 16.7%). During
- the most recent 2-week period ending 20 January 2024, JN.1 accounted for 73.1% of
- 137 sequenced samples, while HV.1 (5.5%) and EG.5 (2.9%) were less prevalent,
- 138 consistent with national data [1].

139 Regarding vaccination status, 675 (10.3%) patients had received XBB.1.5 vaccination

140 (a median of 57 days earlier [IQR:39-73; range:7-122]), 1,155 (17.6%) had received

141 BA.4/BA.5 vaccination (but not XBB.1.5 vaccination) (median of 374 days since last

- dose [IQR:330-414]), 2,879 (43.9%) had received wild-type vaccination (but not
- 143 BA.4/BA.5 or XBB.1.5 vaccination) (median of 712 days since last dose [IQR:625-818]),
- and 1,842 (28.1%) were unvaccinated. Among XBB.1.5-vaccinated patients, the median

145	time since vaccination was 64 days for JN.1 infections (IQR:51-80) and 52 days for
146	XBB-lineage infections (IQR:31-64). In the most recent 14-day period, 19.4% of patients
147	overall were XBB.1.5-vaccinated.
148	Among all SARS-CoV-2 infections, 6.1% of patients with inpatient/ED visits had
149	received XBB.1.5 vaccination, compared to 12.0% of patients with outpatient visits
150	(Figure 1). In multivariable analysis, XBB.1.5 vaccination vs no XBB.1.5 vaccination was
151	associated with lower odds of having inpatient/ED visits compared to outpatient visits
152	(aOR=0.41; 95%CI:0.32-0.53). This protective association was significant among any-
153	variant infections regardless of the specific reference group used: vs BA.4/BA.5
154	vaccination (aOR=0.60; 95%CI:0.45-0.79); vs wild-type vaccination (aOR=0.48;
155	95%CI:0.37-0.63); and vs unvaccinated (aOR=0.24; 95%CI:0.19-0.32).
156	When stratifying by variant, patients with XBB.1.5 vaccination (vs. no XBB.1.5
157	vaccination) had lower odds of inpatient/ED visits among JN.1 infections (aOR=0.62;
158	95%CI:0.40-0.96) and among XBB-lineage infections (aOR=0.28; 95%CI:0.18-0.43)
159	(Figure 1), but this association was weaker among JN.1 vs XBB-lineage infections
160	(vaccination-variant interaction, p=0.003). This interaction between vaccination and
161	JN.1 vs XBB-lineage variant remained significant when comparing XBB.1.5-vaccinated
162	patients to BA.4/BA.5-vaccinated (p=0.009), wild-type-vaccinated (p=0.003), and
163	unvaccinated (p=0.035) patients. Regarding specific vaccination status reference
164	groups, protective associations for XBB.1.5 vaccination were strongest when comparing
165	XBB.1.5-vaccinated to unvaccinated patients.

9

166	In additional analyses, findings were similar when only including adults aged ≥65 years
167	(Supplementary Figure 1; interaction between XBB.1.5 vaccination and JN.1 vs XBB-
168	lineage variant, p=0.043), when comparing only inpatient vs outpatient visits
169	(Supplementary Figure 2; interaction, p=0.013), and when excluding patients with
170	respiratory virus coinfections (Supplementary Figure 3; interaction, p=0.005). Among
171	JN.1 and XBB-lineage infections, similar protective associations were detected for
172	patients XBB.1.5-vaccinated 7-59 days earlier and ≥60 days earlier (Supplementary
173	Figure 4). BA.4/BA.5 vaccination and wild-type vaccination were also associated with
174	lower odds of inpatient/ED visits compared to unvaccinated (Supplementary Figure 5).

### 175 **DISCUSSION**

176 In this multi-state study of adults with medically attended SARS-CoV-2 infection 177 between September 2023 and January 2024, XBB.1.5 mRNA-vaccinated individuals had an overall 59% lower odds of having an inpatient/ED visit vs outpatient visit. Unlike 178 179 previous observational studies examining XBB.1.5 vaccination and severe COVID-19 180 outcomes [8,9,11,14], our study provides novel data on XBB.1.5 vaccine-associated 181 protection against specific contemporary circulating variants, which was made possible 182 through the linkage of viral sequencing and patient-level EHR data. While findings 183 provide evidence that XBB.1.5 vaccines protected against severe illness associated 184 with both JN.1 and XBB-lineage variants, protection against JN.1 was significantly 185 lower. Among JN.1-infected patients, XBB.1.5 vaccination was associated with 38% 186 lower odds of inpatient/ED visits, compared to the 72% lower odds observed among 187 XBB-lineage-infected patients. Given that associations among JN.1-infected individuals 188 were similar irrespective of time since XBB.1.5 vaccination, this difference by variant

10

was not attributed to waning effectiveness over the approximately 4 months of available
data. Similarly, a study evaluating XBB.1.5 vaccine effectiveness against symptomatic
infection reported lower point estimates for likely-JN.1 infections (non-confirmed) than
for non-JN.1 lineages [10]. This key finding emphasizes the need for COVID-19
vaccines to be routinely updated to align with circulating strains and for individuals to
stay up to date with recommended vaccines.

195 The inverse association between XBB.1.5 vaccination (administered a median of 57 196 days earlier) and inpatient/ED visit type was consistently observed regardless of the 197 specific reference group used, which included prior receipt of BA.4/BA.5 vaccination 198 without XBB.1.5 vaccination. Thus, XBB.1.5-vaccine-associated protection was 199 enhanced beyond the remaining immunity conferred by previous BA.4/BA.5 vaccination. 200 It is important to note that results were obtained within the context of widespread natural 201 immunity from prior infection, which could have resulted in attenuated associations if 202 individuals who had not received XBB.1.5 vaccination were more likely to have 203 infection-induced immunity.

204 This study has several limitations. First, although all patients had laboratory-confirmed 205 SARS-CoV-2 infection identified at a medical visit, we were unable to confirm 206 symptomatic COVID-19 and we lacked data on the reasons for medical visits. Second, 207 visit type was solely assessed at the time of sample collection for SARS-CoV-2 testing 208 and it is unknown whether outpatients subsequently had ED or inpatient visits later in 209 the course of infection, potentially contributing to misclassification. Third, we lacked data 210 on social factors (e.g., insurance type) and underlying medical conditions, which could 211 have resulted in residual confounding. Fourth, misclassification of vaccination status is

212	possible if vaccine doses documented in EHRs were not complete. Finally, because
213	vaccination status subgroups were distinct both in vaccine type received and in time
214	from last vaccination, it is not possible to discern whether the protective effect shown
215	here is attributable primarily to vaccine type or titers of neutralizing antibodies.
216	The findings from this study provide evidence of the effectiveness of the XBB.1.5-
217	adapted mRNA vaccines in protecting against severe illness requiring inpatient or ED
218	visits among adults infected with JN.1 or XBB-lineage variants. These results support
219	the current recommendation that all adults should, irrespective of their previous COVID-
220	19 vaccination history, receive the 2023-2024 COVID-19 vaccine to enhance their
221	protection. However, findings also suggest that XBB.1.5 vaccines provide comparatively
222	less protection against the currently predominant JN.1 variant than they do against
223	XBB-lineage variants. Future research is needed to confirm the degree of XBB.1.5
224	vaccine protection against severe illness associated with JN.1 variant infection and to
225	evaluate the potential for waning effectiveness over time.

12

# 226 **NOTES**

227	Author contributions. All authors contributed substantively to this manuscript in the
228	following ways: conceptualization (MEL, VC, SL), investigation (MEL, VC, PRH, DM,
229	JDG, RED, CAS, WBG, LMM, DW, ADR, HD, MI, NLW, TB, KT, JN, JR, ES, SL), data
230	curation (MEL, VC, LMM, DW, ADR, HD, MI, NLW, SL), formal analysis (MEL), project
231	administration (PRH, JDG, CAS, ETC, NLW, WL, JL, SL), writing - original draft (MEL),
232	and writing - review and editing (MEL, VC, PRH, DM, JDG, RED, CAS, WBG, ETC, SL).
233	Acknowledgements. The authors thank the Helix Clinical Informatics and
234	Bioinformatics teams for their contributions to electronic health record data and viral
235	sequencing pipelines. They also thank Catherine Clinton for her oversight and guidance
236	in ensuring research compliance. They thank the investigators and staff at
237	HealthPartners, Providence Health, and the Medical University of South Carolina who
238	contributed to the ViEW Network <sup>™</sup> .
239	<i>Financial support.</i> This work was supported by Helix.
240	Potential conflicts of interest. MEL, VC, LMM, ETC, DW, ADR, HD, MI, NLW, TB, KT,
241	JN, JR, ES, WL, JL, and SL are employees of Helix, Inc. MEL, MI, and SL report
242	contracted research from Pfizer. MEL, MI, WL, and SL report contracted research from
243	the Centers for Disease Control and Prevention (CDC). MEL reports contracted
244	research and travel support from Novavax. PRH reports contracted research from
245	Seegene USA and Helix, Inc. JDG reports contracted research from Helix, Gilead, Eli
246	Lilly, and Regeneron; grants from Merck (BARDA) and Gilead; speaking honoraria and

247 personal fees from Gilead Sciences, Inc, and Eli Lilly & Co; and collaborative services

- 248 agreements with Adaptive Biotechnologies, Monogram Biosciences, and LabCorp; and
- serving as a speaker or advisory board member for Gilead and Eli Lilly. CAS reports
- giving educational lectures sponsored by Eli Lilly. DM, RED, and WBG report no
- 251 potential conflicts.

14

# 252 **REFERENCES**

- 253 1. Centers for Disease Control and Prevention. COVID data tracker: variant
- proportions. 2024. Available from: https://covid.cdc.gov/covid-data-tracker/#variant-
- proportions. Accessed 4 March 2024.
- 256 2. Regan JJ, Moulia DL, Link-Gelles R, et al. Use of updated COVID-19 vaccines
- 257 2023–2024 formula for persons aged ≥6 months: recommendations of the Advisory
- 258 Committee on Immunization Practices United States, September 2023. Morb
- 259 Mortal Wkly Rep **2023**; 72:1140-6.
- 260 3. Yang S, Yu Y, Xu Y, et al. Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under
- heavy immune pressure. Lancet Infect Dis **2024**; 24:e70-2.
- 262 4. Planas D, Staropoli I, Michel V, et al. Distinct evolution of SARS-CoV-2 Omicron
- 263 XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
- bioRxiv [Preprint]. November 21, 2023 [cited 2024 Mar 4]. Available from:
- 265 https://www.biorxiv.org/content/10.1101/2023.11.20.567873v1.
- 5. Kaku Y, Okumura K, Padilla-Blanco M, et al. Virological characteristics of the
  SARS-CoV-2 JN.1 variant. Lancet Infect Dis **2024**; 24:e82.
- 268 6. Wang Q, Guo Y, Bowen A, et al. XBB.1.5 monovalent mRNA vaccine booster
- 269 elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants.
- bioRxiv [Preprint]. December 6, 2023 [cited 2024 Mar 4]. Available from:
- 271 https://www.biorxiv.org/content/10.1101/2023.11.26.568730v2.

272	7.	Chalkias S, McGhee N, Whatley JL, et al. Interim report of the reactogenicity and
273		immunogenicity of SARS-CoV-2 XBB-containing vaccines. J Infect Dis 2024;
274		jiae067. doi: 10.1093/infdis/jiae067.
275	8.	Hansen CH, Moustsen-Helms IR, Rasmussen M, Søborg B, Ullum H, Valentiner-
276		Branth P. Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine
277		against hospitalisation in Denmark: a national cohort study. Lancet Infect Dis 2024;
278		24:e73-4.
279	9.	Werkhoven CH van, Valk A-W, Smagge B, et al. Early COVID-19 vaccine
280		effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive
281		care, the Netherlands, 9 October to 5 December 2023. Euro Surveill 2024;
282		29:2300703.
283	10.	Link-Gelles R, Ciesla AA, Mak J, et al. Early Estimates of updated 2023-2024
284		(monovalent XBB.1.5) COVID-19 vaccine effectiveness against symptomatic
285		SARS-CoV-2 infection attributable to co-circulating Omicron variants among
286		immunocompetent adults - Increasing Community Access to Testing Program,
287		United States, September 2023-January 2024. Morb Mortal Wkly Rep 2024; 73:77-
288		83.
289	11.	Tartof SY, Slezak JM, Frankland TB, et al. BNT162b2 XBB1.5-adapted vaccine and
290		COVID-19 hospital admissions and ambulatory visits in US adults. medRxiv
291		[Preprint]. December 28, 2023 [cited 2024 Mar 4]. Available from:
292		https://www.medrxiv.org/content/10.1101/2023.12.24.23300512v1.

- 12. Skowronski DM, Zhan Y, Kaweski SE, et al. 2023/24 mid-season influenza and
- 294 Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel
- 295 Practitioner Surveillance Network (SPSN). Euro Surveill **2024**; 29. doi: doi:
- 296 10.2807/1560-7917.ES.2024.29.7.2400076.
- 13. Huiberts AJ, Hoeve CE, Gier B de, et al. Effectiveness of Omicron XBB.1.5 vaccine
- against SARS-CoV-2 Omicron XBB and JN.1 infection in a prospective cohort
- study in the Netherlands, October 2023 to January 2024. medRxiv [preprint].
- 300 February 17, 2024 [cited 2024 Mar 4]. Available from:
- 301 https://www.medrxiv.org/content/10.1101/2024.02.15.24302872v1.
- 302 14. DeCuir J. Payne AB, Self WH, et al. Interim effectiveness of updated 2023–2024
- 303 (monovalent XBB.1.5) COVID-19 vaccines against COVID-19–associated
- 304 emergency department and urgent care encounters and hospitalization among
- immunocompetent adults Aged ≥18 years VISION and IVY Networks,
- 306 September 2023–January 2024. Morb Mortal Wkly Rep **2024**; 73:180-8.
- 307 15. Bolze A, Basler T, White S, et al. Evidence for SARS-CoV-2 Delta and Omicron co-
- 308 infections and recombination. Med. **2022**; 3(12):848-59.e4.

17

#### Visit type Overall Inpatient ED Outpatient (n=6,551), (n=1,012), (n=900), (n=4,639), Characteristic No. (%) No. (%) No. (%) No. (%) Health system **HealthPartners** 5,466 (83.4) 4,452 (96.0) 448 (44.3) 566 (62.9) Medical University of South Carolina 202 (3.1) 113 (11.2) 61 (6.8) 28 (0.6) **Providence Health and Services** 883 (13.5) 451 (44.6) 273 (30.3) 159 (3.4) Month of specimen collection September 2023 410 (6.3) 62 (6.1) 62 (6.9) 286 (6.2) October 2023 1,385 (21.1) 251 (24.8) 185 (20.6) 949 (20.5) November 2023 1,604 (24.5) 220 (21.7) 223 (24.8) 1,161 (25.0) December 2023 2,316 (35.4) 316 (31.2) 307 (34.1) 1,693 (36.5) January 2024 836 (12.8) 163 (16.1) 123 (13.7) 550 (11.9) Age group 18 to 49 y 2,684 (41.0) 138 (13.6) 387 (43.0) 2,159 (46.5) 50 to 64 y 1,428 (21.8) 163 (16.1) 1,089 (23.5) 176 (19.6) 65 to 74 y 1,106 (16.9) 246 (24.3) 137 (15.2) 723 (15.6) 75 to 84 y 904 (13.8) 270 (26.7) 135 (15.0) 499 (10.8) ≥85 y 429 (6.5) 195 (19.3) 65 (7.2) 169 (3.6) Female 3,893 (59.4) 505 (49.9) 523 (58.1) 2,865 (61.8) Race and ethnicity Asian, non-Hispanic 325 (5.0) 23 (2.3) 20 (2.2) 282 (6.1) Black, non-Hispanic 828 (12.6) 88 (8.7) 146 (16.2) 594 (12.8)

256 (3.9)

18 (1.8)

41 (4.6)

197 (4.2)

Hispanic

### **Table 1. Patient Characteristics Overall and Stratified by Visit Type.**

18

White, non-Hispanic	3,851 (58.8)	432 (42.7)	413 (45.9)	3,006 (64.8)
Other or unknown	1,291 (19.7)	451 (44.6)	280 (31.1)	560 (12.1)
COVID-19 vaccination status <sup>a</sup>				
Unvaccinated	1,842 (28.1)	360 (35.6)	358 (39.8)	1,124 (24.2)
Vaccinated with a wild-type vaccine	2,879 (43.9)	397 (39.2)	386 (42.9)	2,096 (45.2)
Vaccinated with a BA.4/BA.5 vaccine	1,155 (17.6)	182 (18.0)	112 (12.4)	861 (18.6)
Vaccinated with an XBB.1.5 vaccine	675 (10.3)	73 (7.2)	44 (4.9)	558 (12.0)
SARS-CoV-2 variant <sup>b</sup>				
JN.1	1,084 (16.5)	139 (13.7)	165 (18.3)	780 (16.8)
HV.1	803 (12.3)	116 (11.5)	114 (12.7)	573 (12.4)
EG.5	746 (11.4)	119 (11.8)	119 (13.2)	508 (11.0)
XBB.1.16.1	379 (5.8)	54 (5.3)	67 (7.4)	258 (5.6)
XBB.1.5	262 (4.0)	44 (4.3)	47 (5.2)	171 (3.7)
НК.3	231 (3.5)	39 (3.9)	33 (3.7)	159 (3.4)
XBB.1.16.6	219 (3.3)	34 (3.4)	43 (4.8)	142 (3.1)
XBB.2.3	209 (3.2)	31 (3.1)	24 (2.7)	154 (3.3)
FL.1.5.1	151 (2.3)	24 (2.4)	26 (2.9)	101 (2.2)
BA.2.86	146 (2.2)	20 (2.0)	23 (2.6)	103 (2.2)
XBB.1.9.1	38 (0.6)	6 (0.6)	5 (0.6)	27 (0.6)
XBB.1.16	37 (0.6)	5 (0.5)	7 (0.8)	25 (0.5)
XBB.1.9.2	20 (0.3)	7 (0.7)	3 (0.3)	10 (0.2)
Other XBB	98 (1.5)	15 (1.5)	9 (1.0)	74 (1.6)
Other non-XBB	57 (0.9)	6 (0.6)	9 (1.0)	42 (0.9)
Insufficient sequencing data	2,071 (31.6)	353 (34.9)	206 (22.9)	1,512 (32.6)

310 Abbreviations: ED, emergency department.

311 <sup>a</sup> Defined by whether there was ≥1 COVID-19 vaccine record prior to the specimen collection date as well as by the date and type of

312 the most recent dose received.

- 313 <sup>b</sup> SARS-CoV-2 variant lineages were assigned using pangolin version 4.3.1. Except for HV.1 and HK.3, sublineages of EG.5 are
- 314 aggregated with EG.5. Except for JN.1, sublineages of BA.2.86 are aggregated with BA.2.86. Except for FL.1.5.1, sublineages of
- 315 XBB.1.9.1 are aggregated with XBB.1.9.1. Except for XBB.1.16.1 and XBB.1.16.6, sublineages of XBB.1.16 are aggregated with
- 316 XBB.1.16. Except for EG.5, HV.1, and HK.3, sublineages of XBB.1.9.2 are aggregated with XBB.1.9.2. Sublineages of each other
- named lineage are aggregated with the respective lineage. JN.1 is also known as BA.2.86.1.1; HV.1 as XBB.1.9.2.5.1.6.1; EG.5 as
- 318 XBB.1.9.2.5; HK.3 as XBB.1.9.2.5.1.1.3; and FL.1.5.1 as XBB.1.9.1.1.5.1.

SARS- CoV-2		Inpatient and ED visits	Outpatient visits	OR (9	5% CI)	Inpatient/ED Inpatient/ED visit visit associated associated with with lower odds higher odds of
variant	COVID-19 vaccination status	No. (%)	No. (%)	Unadjusted	Adjusted	of prior XBB.1.5 prior XBB.1.5 vaccination vaccination
Any	XBB.1.5 vaccine	117 (6.1)	558 (12.0)			¯ ← ¦ →
	vs no XBB.1.5 vaccine	1,795 (93.9)	4,081 (88.0)	0.48 (0.39-0.59)	0.41 (0.32-0.53)	HeH i
	vs BA.4/BA.5 vaccine	294 (15.4)	861 (18.6)	0.61 (0.48-0.78)	0.60 (0.45-0.79)	<b>⊢●</b> ⊣ !
	vs wild-type vaccine	783 (41.0)	2,096 (45.2)	0.56 (0.45-0.70)	0.48 (0.37-0.63)	⊢●┥╎
	vs unvaccinated	718 (37.6)	1,124 (24.2)	0.33 (0.26-0.41)	0.24 (0.19-0.32)	i i
JN.1	XBB.1.5 vaccine	47 (15.5)	156 (20.0)	_	_	
	vs no XBB.1.5 vaccine	257 (84.5)	624 (80.0)	0.73 (0.51-1.05)	0.62 (0.40-0.96)	⊢ <b>●</b> ₋¦
	vs BA.4/BA.5 vaccine	46 (15.1)	158 (20.3)	1.03 (0.65-1.64)	0.97 (0.56-1.68)	<b>⊢</b>
	vs wild-type vaccine	98 (32.2)	281 (36.0)	0.86 (0.58-1.29)	0.82 (0.49-1.37)	⊢_ <b>●</b> <u> </u>
	vs unvaccinated	113 (37.2)	185 (23.7)	0.49 (0.33-0.74)	0.31 (0.19-0.52)	⊢ <b>●</b> → i
XBB (any)	XBB.1.5 vaccine	35 (3.5)	187 (8.5)	_	_	
	vs no XBB.1.5 vaccine	956 (96.5)	2,015 (91.5)	0.39 (0.27-0.57)	0.28 (0.18-0.43)	
	vs BA.4/BA.5 vaccine	166 (16.8)	406 (18.4)	0.46 (0.31-0.69)	0.40 (0.25-0.63)	<b>⊢</b> ●1
	vs wild-type vaccine	429 (43.3)	1,071 (48.6)	0.47 (0.32-0.68)	0.33 (0.21-0.52)	<b>⊢</b> ●→
	vs unvaccinated	361 (36.4)	538 (24.4)	0.28 (0.19-0.41)	0.17 (0.11-0.26)	<b>⊢</b> ●1
HV.1	XBB.1.5 vaccine	9 (3.9)	63 (11.0)	_	_	
	vs no XBB.1.5 vaccine	221 (96.1)	510 (89.0)	0.33 (0.16-0.67)	0.22 (0.10-0.49)	<b>⊢_</b> ●i
	vs BA.4/BA.5 vaccine	46 (20.0)	128 (22.3)	0.40 (0.18-0.86)	0.34 (0.14-0.83)	⊢•i
	vs wild-type vaccine	97 (42.2)	247 (43.1)	0.36 (0.17-0.76)	0.22 (0.09-0.51)	⊢ <b>−</b> • !
	vs unvaccinated	78 (33.9)	135 (23.6)	0.25 (0.12-0.52)	0.15 (0.06-0.34)	<b>← ← ↓</b>
EG.5	XBB.1.5 vaccine	8 (3.4)	34 (6.7)	_	_	
	vs no XBB.1.5 vaccine	230 (96.6)	474 (93.3)	0.48 (0.22-1.06)	0.33 (0.14-0.81)	<b>⊢</b> •
	vs BA.4/BA.5 vaccine	39 (16.4)	81 (15.9)	0.49 (0.21-1.15)	0.44 (0.16-1.16)	⊢ŧ
	vs wild-type vaccine	106 (44.5)	282 (55.5)	0.63 (0.28-1.40)	0.39 (0.15-0.98)	⊢į
	vs unvaccinated	85 (35.7)	111 (21.9)	0.31 (0.14-0.70)	0.22 (0.08-0.56)	<b>⊢</b>

320 Figure 1. Association between inpatient or emergency department vs outpatient visit type and prior receipt of an

**XBB.1.5 vaccine.** Associations were calculated among all SARS-CoV-2 infections and among JN.1, XBB (any

sublineage), HV.1, and EG.5 infections. Odds ratios (ORs) were calculated comparing prior receipt of an XBB.1.5 vaccine to no prior receipt of an XBB.1.5 vaccine (irrespective of previous COVID-19 vaccination history) as well as to each of three specific reference groups: 1) prior receipt of a BA.4/BA.5 vaccine but not an XBB.1.5 vaccine; 2) prior receipt of a wild-type vaccine but not a BA.4/BA.5 or XBB.1.5 vaccine; and 3) unvaccinated.. Adjusted ORs were adjusted for age group (18-49, 50-64, 65-74, 75-84, and ≥85 years), sex, race and ethnicity (Asian, non-Hispanic; Black, non-Hispanic; Hispanic; white, non-Hispanic; and other/unknown), health system and state of residence, and collection date (natural cubic spline with 4 degrees of freedom). CI indicates confidence interval; ED, emergency department.